Eurofins Scientific (ERF) Q2 2024 earnings summary

Executive summary

• Achieved record H1 2024 revenues of €3,419m, up 6.5% year-over-year, driven by organic growth and acquisitions, surpassing pre-pandemic levels without COVID-19 related revenues.

• Adjusted EBITDA rose 18.3% to €757m (22.1% margin), with margin improving 220bps year-over-year; reported EBITDA margin improved to 20.9% (+260bps).

• Net profit increased 46% to €220m; basic EPS rose 57% to €1.01; free cash flow to the firm surged 276% to €279m.

• Financial leverage reduced to 1.9x, with no major financing needs for 2024 and access to over €1bn in undrawn credit lines.

• Continued strong M&A activity, digitalisation, and infrastructure investments, including 15 acquisitions, 18 new start-up labs, and 45,000m² net laboratory space added.

Financial highlights

• Core Business organic revenue growth of 5.6% year-over-year, excluding COVID-19 related revenues.

• Adjusted EBITDA: €757m (22.1% margin), up from €640m (19.9%) in H1 2023.

• Free cash flow to the firm: €279m (+276% year-over-year); cash conversion improved to 39%.

• Net working capital intensity reduced to 6.3% of revenues, with better DSOs and DPOs.

• Early redemption of €448m Eurobond in June 2024, reducing near-term refinancing needs.

Outlook and guidance

• FY 2024 revenue target: €7.075–7.175bn; adjusted EBITDA: €1.525–1.575bn; FCFF before investment in owned sites: €800–840m.

• Mid-term (2027) targets: revenues approaching €10bn, margin 24%, FCFF before investment in owned sites approaching €1.5bn, leverage below 1.5x.

• Organic growth target of 6.5% p.a. and €250m annual revenue from acquisitions through 2027.

• No quarterly guidance; objectives set annually unless significant events occur.

• Positive outlook for H2, with further margin and cash flow improvements expected as investments yield efficiencies.